All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The U.S. Food and Drug Administration (FDA) announced the clearance of the Investigational New Drug Application of CFT7455, a monofunctional degradation activating compound (monoDAC) that targets IKZF1/3.1 This orally available compound is designed to treat multiple myeloma (MM) and non-Hodgkin lymphomas (NHLs).
CFT7455 as a monoDAC is thought to act by binding to E3 ligases and creating an improved binding surface for the target protein, causing degradation. The targets IKZF1/3, are transcription factors involved in the proliferation of MM and NHL cells.2
Having passed its 30-day safety review and achieving FDA clearance means that CFT7455 can proceed to a phase I/II clinical trial in patients with relapsed/refractory MM and NHL. The phase I portion will investigate CFT7455 alone and combined with dexamethasone. Once the optimal dose has been found, the phase II trial will be initiated with the primary endpoints of safety and tolerability. The secondary endpoints will be the characterization of the pharmacokinetic and pharmacodynamic profiles, along with the antitumor activity of CFT7455.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox